Pharmafile Logo

payer survey

- PMLiVE

FDA sets November date for expert panel review of Biogen’s aducanumab

Advisory committee will review biologics license application for controversial therapy

- PMLiVE

Responding to dynamic shifts in value communications

OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies.

OPEN Health

- PMLiVE

Taking a holistic approach to patient care

The importance of recognising each patient as an individual

- PMLiVE

Diversity and inclusion

It may not be something we can change overnight, but it is certainly something we need to start to address now

- PMLiVE

Phase 1/2a results for J&J’s COVID-19 vaccine show early promise

Vaccine produced neutralising antibodies in 98% of participants

AstraZeneca AZ

EU will shoulder certain liability costs in AZ COVID-19 vaccine deal

Low-cost deal will see the EU assume responsibility for side-effect claims

The concordance conundrum: the tech divide

COVID-19 resulted in the rapid adoption of virtual consultations; while they offer increased accessibility and convenience for some, are they really all they are cracked up to be? Consultations in...

Page & Page Health

- PMLiVE

J&J advances COVID-19 vaccine into phase 3 testing

News comes after last week's announcement from Novavax on its launch of a UK-based phase 3 trial

- PMLiVE

Q&A: Isabel Gibson

PME interviews W2O ISO's Managing Director

- PMLiVE

Pearls of wisdom

The Americas have been ravaged by COVID-19 – here are some important lessons we have learned

- PMLiVE

Novavax starts first phase 3 COVID-19 vaccine trial in the UK

Trial is set to enrol up to 10,000 participants aged 18-84

- PMLiVE

Lilly’s Verzenio scores a win in early-stage breast cancer

Positive data was presented at 2020 ESMO virtual congress

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links